medigraphic.com
Colegio de Medicina Interna de México.

2021, Número 5

<< Anterior Siguiente >>

Med Int Mex 2021; 37 (5)


Pioglitazona, una alternativa efectiva aún vigente para el control de la diabetes tipo 2

González-Ortiz M, Castro-Martínez MG, Solís-Herrera C, Alexanderson-Rosas EG, Márquez-Rodríguez E, Garduño-Pérez ÁA, Servin-Caamaño AI, Duarte-Vega M, Martínez-Abundis E, Morales-Villegas EC, Violante-Ortiz RM

Idioma: Español
Referencias bibliográficas: 38
Paginas: 800-812
Archivo PDF: 267.55 Kb.


RESUMEN

El presente documento consiste en una revisión compactada de la pioglitazona, una tiazolidinediona que a lo largo de los años ha mostrado múltiples efectos benéficos en el tratamiento de la diabetes tipo 2 que van más allá del control glucémico y cuya descripción pretende otorgarle a esta glitazona el justo valor que tiene en el momento actual dentro del arsenal terapéutico y de las recomendaciones internacionales para el manejo de los pacientes con esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118. doi: 10.1056/NEJMra041001.

  2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. doi: 10.1056/ NEJMoa072761.

  3. Sourij H, Waschers TC. Pioglitazone in the management of type 2 diabetes and beyond. Therapy 2007; 4: 517-533. Doi. 10.2217/14750708.4.5.517.

  4. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523. doi: 10.2337/diacare.25.3.517.

  5. Walter H, Lübben G. Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus. Drugs 2005; 65: 1-13. doi: 10.2165/00003495- 200565010-00001.

  6. González-Ortiz M, Hernández-Salazar E, Kam-Ramos AM, Martínez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 75: 115-118. doi: 10.1016/j.diabres.2006.05.003.

  7. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547- 1554. doi: 10.2337/diacare.28.7.1547.

  8. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478. doi: 10.1210/jc.2003-030723.

  9. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary diabetes management algorithm. Endocr Pract 2020; 26: 107-139. doi: 10.4158/CS-2019-0472.

  10. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2020. Diabetes Care 2020; 43 (Suppl. 1): S98-S110. doi: 10.2337/dc20-S009.

  11. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep 2019; 19: 151. doi: 10.1007/ s11892-019-1270-y.

  12. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled doseresponse study. The pioglitazone 001 study group. Diabetes Care 2000; 23: 1605-1611. doi: 10.2337/diacare.23.11.1605.

  13. Schneider R, Lessem J, Lekich R. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes 1999; 48 (Suppl 1): A109.

  14. Blanco AJ, Domingo MP. Agentes orales en la diabetes mellitus tipo 2: terapia combinada precoz frente a tratamiento clásico escalonado. Av Diabetol 2009; 25: 219-221.

  15. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49: 434-441. doi: 10.1007/s00125-006-0141-7.

  16. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60: 1577-1585. doi: 10.1007/s00125-017-4342-z.

  17. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The pioglitazone 027 study group. Clin Ther 2000; 22: 1395- 1409. doi: 10.1016/s0149-2918(00)83039-8.

  18. Pérez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009; 25: 2915-2923. doi: 10.1185/03007990903350011.

  19. Schöndorf T, Musholt PB, Hohberg C, Forst T, Lehmann U, Fuchs W, et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol 2011; 5: 426- 432. doi: 10.1177/193229681100500233.

  20. Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine (Baltimore) 2018; 97: e12633. doi: 10.1097/ MD.0000000000012633.

  21. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010; 33: 2406-2408. doi: 10.2337/dc10-0159.

  22. Kaku K, Itayasu T, Hirosi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 2011; 13: 1028-1035. doi: 10.1111/j.1463-1326.2011.01460.x.

  23. Alba M, Ahrén B, Inzucchi SE, Guan Y, Mallick M, Xu L, et al. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes Obes Metab 2013; 15: 1101-1110. doi: 10.1111/dom.12145.

  24. Dorkhan M, Frid A. Review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag 2007; 3: 721-731.

  25. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallelgroup trial. Clin Ther 2004; 26: 744-754. doi: 10.1016/ s0149-2918(04)90074-4.

  26. Vaccaro O, Masuli M, Nicolluci A, Bonara E, Del Prato S, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887-897. doi: 10.1016/S2213-8587(17)30317-0.

  27. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 study group. Efficacy and safety of pioglitazone in Type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.

  28. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478. doi: 10.2337/dc11-1693.

  29. Ryder REJ. DeFronzo RA. Diabetes medications with cardiovascular protection-what now after LEADER? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? Br J Diabetes 2016; 16: 103-106.

  30. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1615-1622. doi: 10.1210/jc.2011-2243.

  31. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011; 13: 1088- 1096. doi: 10.1111/j.1463-1326.2011.01463.x.

  32. Pratley RE, Reusch JEB, Fleck PR, Wilson CA, Mekkic Q, Alogliptin study 009 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361-2371. doi: 10.1185/03007990903156111.

  33. US Department of health and human services food and drug administration. Guidance for industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/ cder/guidance/index.htm.

  34. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289. doi: 10.1016/S0140- 6736(05)67528-9.

  35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188. doi: 10.1001/jama.298.10.1180.

  36. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR γ agonists: time for a reassessment. Trends Endocrinol Metabol 2012; 23: 206-212. doi: 10.1016/j. tem.2012.03.001.

  37. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70: 1945-1961. doi: 10.2165/11538100-000000000-00000.

  38. Schernthaner G, Currie CJ, Schernthaner G-H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013; 36 (Suppl. 2): S155-S161. doi: 10.2337/dcS13-2031.




2020     |     www.medigraphic.com